MC Sciences is worldwide in a unique position to secure a first-in-class novel mast cell therapy platform.
Clinical Human Proof-of-Concept
High probability for clinical phase success based on proven in-human efficacy results.
Therapy platform builds upon a novel discovered target and a new class of substances with clearly identified pharmacophore.
Expected good safety profile based on experience of first in-human clinical tests with substance derivatives.
Focus on clinical indications with high unmet clinical needs and further large line extension potential.